New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
10:34 EDTAPRI, TKPYYApricus Biosciences reports Takeda accepts first shipment of Vitaros
Apricus Biosciences (APRI) announced earlier that Takeda Pharmaceuticals (TKPYY), the company's partner in the United Kingdom, has accepted the first shipment of Vitaros, Apricus' topical treatment for erectile dysfunction. Apricus CEO Richard Pascoe said, "With the commercial availability of Vitaros in the United Kingdom, Takeda is in a position to finalize its pre-launch activities in an effort to be the first Vitaros commercial partner to offer an on demand topical cream treatment for men with erectile dysfunction." Shares of Apricus are up about 16% to $2.34 in morning trading.
News For APRI;TKPYY From The Last 14 Days
Check below for free stories on APRI;TKPYY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
07:35 EDTAPRIApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 12, 2014
07:28 EDTAPRIApricus Biosciences files $100M mixed securities shelf
Subscribe for More Information
07:07 EDTAPRIAspire Capital purchases 1.16M shares of Apricus Biosciences for $2M
Subscribe for More Information
07:05 EDTAPRIApricus Biosciences reports Q2 EPS 5c, consensus (4c)
Reports Q2 revenue $5.5M, consensus $5.45M.
August 9, 2014
15:22 EDTTKPYYMillennium gets FDA approval for Velcade for retreatment of multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use